Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vericel Corproation (NQ: VCEL )

28.24 -0.06 (-0.21%)
Streaming Delayed Price Updated: 10:54 AM EDT, May 16, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 53,223
Open 28.11
Bid (Size) 28.13 (2)
Ask (Size) 28.26 (1)
Prev. Close 28.30
Today's Range 27.47 - 28.74
52wk Range 25.11 - 68.94
Shares Outstanding 46,631,158
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Vericel: Q1 Earnings Insights
Vericel (NASDAQ:VCEL) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Scheduled For May 4, 2022
Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million. 
Via Benzinga

Performance

YTD
-31.24%
-31.24%
1 Month
-19.68%
-19.68%
3 Month
-20.63%
-20.63%
6 Month
-31.69%
-31.69%
1 Year
-44.65%
-44.65%

More News

Read More
Vericel Q1 2022 Earnings Conference Call On May 4, 2022 At 08:30 AM ET
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Recap: Vericel Q3 Earnings
Via Benzinga
Understanding Vericel's Unusual Options Activity
Via Benzinga
88 Biggest Movers From Yesterday
Via Benzinga
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
Via Benzinga
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly
Via Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Jim Cramer Believes Penn National Is A Winner, Likes Vericel
Via Benzinga
Vericel (VCEL) Q3 2021 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Earnings Scheduled For November 9, 2021
Via Benzinga
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Via Benzinga
Vericel (VCEL) Q2 2021 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
Via Benzinga
Earnings Scheduled For August 4, 2021
Via Benzinga
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Via Benzinga
Exposures Product Safety
58 Biggest Movers From Yesterday
Via Benzinga
Why Vericel Tumbled by Nearly 15% on Tuesday
Via The Motley Fool
Exposures Product Safety
Why Shares Of MediWound And Vericel Fell On Tuesday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.